首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TARC |
| Uniprot No | Q92583 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-94aa |
| 氨基酸序列 | ARGTNVGRECCLEYFKGAIPLRKLKTWYQTSEDCSRDAIVFVTVQGRAIC SDPNNKRVKNAVKYLQSLERS |
| 预测分子量 | 81 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的3篇关于TARC重组蛋白的参考文献示例，供学术写作参考：
1. **文献名称**
*Expression and Functional Characterization of Recombinant Human TARC/CCL17 in Mammalian Cells*
**作者**: Smith J, Tanaka K, et al.
**摘要**：本研究利用HEK293细胞系统成功表达重组人TARC蛋白，并通过亲和层析纯化。功能实验表明，重组TARC可特异性趋化CCR4+ T细胞，并在纳摩尔浓度下激活下游信号通路，证实其生物活性与天然蛋白一致。
2. **文献名称**
*Structural Insights into TARC-CCR4 Interaction by Crystallography of Recombinant Protein Complex*
**作者**: Müller R, Sato H, et al.
**摘要**：通过X射线晶体学解析重组TARC蛋白与CCR4受体的复合物三维结构(分辨率2.8Å)，发现N端β-片层结构域为关键结合位点。该研究为开发靶向TARC-CCR4轴的特异性抑制剂提供了结构基础。
3. **文献名称**
*Recombinant TARC Enhances Th2 Polarization in Atopic Dermatitis Model*
**作者**: Chen L, Park S, et al.
**摘要**：在小鼠特应性皮炎模型中，皮下注射重组TARC蛋白显著增加局部IL-4/IL-5分泌，并促进CD4+ CCR4+ T细胞浸润。研究表明重组TARC可通过调控Th2型免疫反应加剧皮肤炎症进程。
---
**注**：以上文献为科研写作示例模板，实际引用请以真实发表的论文为准。建议通过PubMed、Web of Science等数据库检索关键词"recombinant TARC/CCL17"获取最新研究。
Thymus and Activation-Regulated Chemokine (TARC/CCL17) is a small secreted protein belonging to the CC chemokine family, primarily recognized for its role in immune regulation and inflammatory responses. It is encoded by the CCL17 gene in humans and functions as a chemoattractant for immune cells expressing its receptor, CCR4. TARC is predominantly produced by dendritic cells, macrophages, endothelial cells, and epithelial cells, particularly in response to pro-inflammatory cytokines like TNF-α or IL-4. Its primary biological function involves recruiting Th2 lymphocytes, regulatory T cells (Tregs), and dendritic cells to sites of inflammation, making it a key mediator in allergic diseases, autoimmune disorders, and certain cancers.
The development of recombinant TARC protein has enabled detailed studies of its structure-function relationships and therapeutic potential. Recombinant TARC is typically produced using expression systems such as E. coli or mammalian cell lines, ensuring high purity and bioactivity. This engineered protein retains the native ability to bind CCR4. allowing researchers to investigate signaling pathways involved in immune cell migration and activation. Its applications span basic research—such as modeling Th2-dominated inflammation in asthma or atopic dermatitis—to drug discovery efforts targeting CCR4-TARC interactions in diseases like cutaneous T-cell lymphoma.
Clinically, elevated TARC levels serve as a biomarker for disease severity in conditions like Hodgkin's lymphoma and eosinophilic pneumonia. Recent studies also explore its role in tumor microenvironments, where TARC may either promote immune evasion or modulate anti-tumor responses. However, the dual nature of TARC in inflammation and immune tolerance continues to drive both interest and challenges in therapeutic targeting. Recombinant TARC remains a vital tool for dissecting these complex biological roles and developing targeted immunomodulatory therapies.
×
